首页 > 最新文献

MDM Policy and Practice最新文献

英文 中文
Patient Perceptions of a Decision Support Tool for Men with Localized Prostate Cancer. 局部前列腺癌患者对决策支持工具的认知。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231156427
Mia Austria, Colin Kimberlin, Tiffany Le, Kathleen A Lynch, Behfar Ehdaie, Thomas M Atkinson, Andrew J Vickers, Sigrid V Carlsson

Purpose. To evaluate patient perceptions of a Web-based decision aid for the treatment of localized prostate cancer. Methods. We assessed patient perceptions of a multicomponent, Web-based decision aid with a preference elicitation/values clarification exercise using adaptive conjoint analysis, the generation of a summary report, and provision of information about localized prostate cancer treatment options. Using a think-aloud approach, we conducted 21 cognitive interviews with prostate cancer patients presented with the decision aid prior to seeing their urologist. Thematic content analysis was used to examine patient perceptions of the tool's components and content prior to engaging in shared decision making with their clinician. Results. Five themes were identified: 1) patients had some negative emotional reactions to the tool, pointing out what they perceived to be unnecessarily negative framing and language used; 2) patients were forced to stop and think about preferences while going through the tool and found this deliberation to be useful; 3) patients were confused by the tool; 4) patients tried to discern the intent of the conjoint analysis questions; and 5) there was a disconnect between patients' negative reactions while using the tool and a contrasting general satisfaction with the final "values profile" created by the tool. Conclusions. Studies are needed to explore the disconnect between patients' expressing negative reactions while going through some components of decision aids but satisfaction with the final output. In particular, we hypothesize that this effect might be explained by cognitive biases such as choice-supportive bias, hindsight bias, and the "IKEA effect." This is one of the first projects to elicit patient reactions while they were completing a decision aid, and we recommend further similar, qualitative postprocess evaluation studies.

Highlights: We explored perceptions of a decision aid with education about localized prostate cancer treatment and preference elicitation using adaptive conjoint analysis.Patients found the tool useful but were also confused by it, tried to discern the intent of the questions, and expressed negative emotional reactions.In particular, there was a disconnect between patients' negative reactions while using the tool and general satisfaction with the final values profile generated by the tool, which is an area for future research.

目的。评估患者对基于网络的决策辅助治疗局限性前列腺癌的看法。方法。我们评估了患者对多组分、基于网络的决策辅助的看法,采用自适应联合分析的偏好启发/价值观澄清练习,生成总结报告,并提供有关局部前列腺癌治疗方案的信息。采用有声思考的方法,我们对21名前列腺癌患者进行了认知访谈,这些患者在去看泌尿科医生之前接受了决策辅助。主题内容分析用于检查患者在与临床医生共同决策之前对工具组成部分和内容的看法。结果。确定了五个主题:1)患者对该工具有一些负面情绪反应,指出他们认为不必要的负面框架和语言使用;2)患者在使用工具时被迫停下来思考偏好,并发现这种思考是有用的;3)患者被工具所迷惑;4)患者试图辨别联合分析问题的意图;5)患者在使用该工具时的负面反应与对该工具最终创建的“价值概况”的对比总体满意度之间存在脱节。结论。需要进行研究,以探索患者在经历决策辅助的某些组成部分时表达的负面反应与对最终输出的满意度之间的脱节。特别是,我们假设这种影响可以用认知偏见来解释,比如选择支持偏见、后见之明偏见和“宜家效应”。这是第一个在患者完成决策辅助时引起患者反应的项目之一,我们建议进一步进行类似的定性后处理评估研究。重点:我们利用适应性联合分析探讨了通过局部前列腺癌治疗教育和偏好启发来辅助决策的认知。患者发现这个工具很有用,但也被它弄糊涂了,他们试图辨别问题的意图,并表现出消极的情绪反应。特别是,患者在使用该工具时的负面反应与对该工具生成的最终值概况的总体满意度之间存在脱节,这是未来研究的一个领域。
{"title":"Patient Perceptions of a Decision Support Tool for Men with Localized Prostate Cancer.","authors":"Mia Austria,&nbsp;Colin Kimberlin,&nbsp;Tiffany Le,&nbsp;Kathleen A Lynch,&nbsp;Behfar Ehdaie,&nbsp;Thomas M Atkinson,&nbsp;Andrew J Vickers,&nbsp;Sigrid V Carlsson","doi":"10.1177/23814683231156427","DOIUrl":"https://doi.org/10.1177/23814683231156427","url":null,"abstract":"<p><p><b>Purpose.</b> To evaluate patient perceptions of a Web-based decision aid for the treatment of localized prostate cancer. <b>Methods.</b> We assessed patient perceptions of a multicomponent, Web-based decision aid with a preference elicitation/values clarification exercise using adaptive conjoint analysis, the generation of a summary report, and provision of information about localized prostate cancer treatment options. Using a think-aloud approach, we conducted 21 cognitive interviews with prostate cancer patients presented with the decision aid prior to seeing their urologist. Thematic content analysis was used to examine patient perceptions of the tool's components and content prior to engaging in shared decision making with their clinician. <b>Results.</b> Five themes were identified: 1) patients had some negative emotional reactions to the tool, pointing out what they perceived to be unnecessarily negative framing and language used; 2) patients were forced to stop and think about preferences while going through the tool and found this deliberation to be useful; 3) patients were confused by the tool; 4) patients tried to discern the intent of the conjoint analysis questions; and 5) there was a disconnect between patients' negative reactions while using the tool and a contrasting general satisfaction with the final \"values profile\" created by the tool. <b>Conclusions.</b> Studies are needed to explore the disconnect between patients' expressing negative reactions while going through some components of decision aids but satisfaction with the final output. In particular, we hypothesize that this effect might be explained by cognitive biases such as choice-supportive bias, hindsight bias, and the \"IKEA effect.\" This is one of the first projects to elicit patient reactions while they were completing a decision aid, and we recommend further similar, qualitative postprocess evaluation studies.</p><p><strong>Highlights: </strong>We explored perceptions of a decision aid with education about localized prostate cancer treatment and preference elicitation using adaptive conjoint analysis.Patients found the tool useful but were also confused by it, tried to discern the intent of the questions, and expressed negative emotional reactions.In particular, there was a disconnect between patients' negative reactions while using the tool and general satisfaction with the final values profile generated by the tool, which is an area for future research.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231156427"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/7e/10.1177_23814683231156427.PMC10009039.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9131721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States. 5个西欧国家和美国肺炎球菌疫苗建议和决策标准的演变
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231174432
Roxane Noharet-Koenig, Katarzyna Lasota, Pascaline Faivre, Edith Langevin

Objectives: Pneumococcal vaccine recommendations have become increasingly complex. This study aims to understand how national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies of 5 European countries and the United States formed their pneumococcal vaccine recommendations, by providing reviewed evidence and key drivers for new recommendations.

Methods: Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and National Health Authorities Web sites were screened to capture the evolution of pneumococcal recommendations. A narrative review was conducted on NITAGs and HTA bodies' Web sites. Assessments of pneumococcal vaccines published from 2009 to 2022 were included.

Results: Thirty-four records were identified including 21 assessments for risk groups, 17 for elderly, and 12 for children. Burden of disease and vaccine characteristics were almost systematically reviewed during assessments. All 6 countries recommended the use of higher-valent pneumococcal vaccine (PCV; i.e., PCV10 and PCV13) in childhood vaccination programs, given their broader serotype coverage and their comparable profile to PCV7. PCV13 was progressively added to the vaccine schedule (in addition to polysaccharide vaccine) in at least the high-risk group, given the high burden in this population and expected additional benefits of PCV13. For the elderly, unlike the United States, European countries issued negative recommendation for PCV13 routine use because of substantial herd effects from childhood vaccination program making PCV13 likely not cost-effective.

Conclusions: This research provides an overview of decision-making processes for higher-valent PCVs recommendations and could be of interest to anticipate the place of next generation of PCVs in the vaccination landscape.

Highlights: By describing evidence-based criteria for decision making, this study emphasizes the framework analysis of NITAGs and HTA bodies when assessing pneumococcal vaccines and demonstrates that variation exists between countries and also according to population evaluated.While the burden of disease and immunogenicity/efficacy data were almost systematically reviewed by national stakeholders, economic assessments were reported to a lesser extent but played a major role in the limited use of PCV13 in the adult population.

目的:肺炎球菌疫苗的建议已变得越来越复杂。本研究旨在了解5个欧洲国家和美国的国家免疫技术咨询小组(NITAGs)和卫生技术评估机构(HTA)如何形成其肺炎球菌疫苗建议,通过提供审查证据和新建议的关键驱动因素。方法:筛选疾病控制和预防中心、欧洲疾病预防和控制中心以及国家卫生当局的网站,以获取肺炎球菌建议的演变。对NITAGs和HTA机构的网站进行了叙述性审查。包括2009年至2022年发表的肺炎球菌疫苗评估。结果:共确定34条记录,其中21条为危险人群评估,17条为老年人评估,12条为儿童评估。在评估期间几乎系统地审查了疾病负担和疫苗特性。所有6个国家都建议使用高价肺炎球菌疫苗(PCV;鉴于其更广泛的血清型覆盖率以及与PCV7相似的特征,将PCV10和PCV13纳入儿童疫苗接种规划。至少在高危人群中,PCV13被逐步添加到疫苗计划中(除了多糖疫苗之外),考虑到该人群的高负担和PCV13的预期额外益处。对于老年人,与美国不同,欧洲国家对常规使用PCV13提出了负面建议,因为儿童疫苗接种计划的大量群体效应使PCV13可能不具有成本效益。结论:本研究概述了高价pcv推荐的决策过程,并可能对预测下一代pcv在疫苗接种领域的地位感兴趣。重点:通过描述基于证据的决策标准,本研究强调在评估肺炎球菌疫苗时对NITAGs和HTA机构进行框架分析,并表明在国家之间以及根据所评估的人群存在差异。虽然国家利益攸关方几乎系统地审查了疾病负担和免疫原性/有效性数据,但报告的经济评估程度较低,但在成人人群中有限使用PCV13方面发挥了主要作用。
{"title":"Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States.","authors":"Roxane Noharet-Koenig,&nbsp;Katarzyna Lasota,&nbsp;Pascaline Faivre,&nbsp;Edith Langevin","doi":"10.1177/23814683231174432","DOIUrl":"https://doi.org/10.1177/23814683231174432","url":null,"abstract":"<p><strong>Objectives: </strong>Pneumococcal vaccine recommendations have become increasingly complex. This study aims to understand how national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies of 5 European countries and the United States formed their pneumococcal vaccine recommendations, by providing reviewed evidence and key drivers for new recommendations.</p><p><strong>Methods: </strong>Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and National Health Authorities Web sites were screened to capture the evolution of pneumococcal recommendations. A narrative review was conducted on NITAGs and HTA bodies' Web sites. Assessments of pneumococcal vaccines published from 2009 to 2022 were included.</p><p><strong>Results: </strong>Thirty-four records were identified including 21 assessments for risk groups, 17 for elderly, and 12 for children. Burden of disease and vaccine characteristics were almost systematically reviewed during assessments. All 6 countries recommended the use of higher-valent pneumococcal vaccine (PCV; i.e., PCV10 and PCV13) in childhood vaccination programs, given their broader serotype coverage and their comparable profile to PCV7. PCV13 was progressively added to the vaccine schedule (in addition to polysaccharide vaccine) in at least the high-risk group, given the high burden in this population and expected additional benefits of PCV13. For the elderly, unlike the United States, European countries issued negative recommendation for PCV13 routine use because of substantial herd effects from childhood vaccination program making PCV13 likely not cost-effective.</p><p><strong>Conclusions: </strong>This research provides an overview of decision-making processes for higher-valent PCVs recommendations and could be of interest to anticipate the place of next generation of PCVs in the vaccination landscape.</p><p><strong>Highlights: </strong>By describing evidence-based criteria for decision making, this study emphasizes the framework analysis of NITAGs and HTA bodies when assessing pneumococcal vaccines and demonstrates that variation exists between countries and also according to population evaluated.While the burden of disease and immunogenicity/efficacy data were almost systematically reviewed by national stakeholders, economic assessments were reported to a lesser extent but played a major role in the limited use of PCV13 in the adult population.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231174432"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/aa/10.1177_23814683231174432.PMC10233586.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10663612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Preferences for Decision Control among a High-Risk Cohort Offered Lung Cancer Screening: A Brief Report of Secondary Analyses from the Lung Screen Uptake Trial (LSUT). 高风险队列肺癌筛查中决策控制的偏好:肺筛查吸收试验(LSUT)的二次分析简要报告
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231163190
Stefanie Bonfield, Mamta Ruparel, Jo Waller, Jennifer L Dickson, Samuel M Janes, Samantha L Quaife

Background. Personal autonomy in lung cancer screening is advocated internationally, but health systems diverge in their approach, mandating either shared decision making (with a health care professional) or individual decision making. Studies of other cancer screening programs have found that individual preferences for the level of involvement in screening decisions vary across different sociodemographic groups and that aligning approaches with individual preferences has the potential to improve uptake. Method. For the first time, we examined preferences for decision control among a cohort of UK-based high-risk lung cancer screening candidates (N = 727). We used descriptive statistics to report the distribution of preferences and chi-square tests to examine associations between decision preferences and sociodemographic variables. Results. Most (69.7%) preferred to be involved in the decision with varying degrees of input from a health care professional. Few (10.2%) wanted to make the decision alone. Preferences were also associated with educational attainment. Conclusion. These findings suggest one-size-fits-all approaches may be inadequate in meeting diverse preferences, particularly those placing sole onus on the individual.

Highlights: Preferences for involvement in decision making about lung cancer screening are heterogeneous among high-risk individuals in the United Kingdom and vary by educational attainment.Further work is needed to understand how policy makers might implement hybrid approaches to accommodate individual preferences and optimize lung cancer screening program outcomes.

背景。国际上提倡肺癌筛查中的个人自主,但卫生系统在方法上存在分歧,要求共同决策(与卫生保健专业人员)或个人决策。对其他癌症筛查项目的研究发现,不同社会人口群体对参与筛查决策水平的个人偏好各不相同,将方法与个人偏好相结合有可能提高接受程度。方法。我们首次在英国高风险肺癌筛查候选人队列(N = 727)中检查了决策控制的偏好。我们使用描述性统计来报告偏好的分布,并使用卡方检验来检验决策偏好与社会人口变量之间的关联。结果。大多数人(69.7%)更愿意在医疗保健专业人员不同程度的参与下参与决策。很少有人(10.2%)想独自做决定。偏好也与教育程度有关。结论。这些发现表明,一刀切的方法可能不足以满足不同的偏好,特别是那些把责任完全放在个人身上的方法。重点:参与肺癌筛查决策的偏好在英国高危人群中存在异质性,且受教育程度不同。需要进一步的工作来了解决策者如何实施混合方法来适应个人偏好并优化肺癌筛查项目的结果。
{"title":"Preferences for Decision Control among a High-Risk Cohort Offered Lung Cancer Screening: A Brief Report of Secondary Analyses from the Lung Screen Uptake Trial (LSUT).","authors":"Stefanie Bonfield,&nbsp;Mamta Ruparel,&nbsp;Jo Waller,&nbsp;Jennifer L Dickson,&nbsp;Samuel M Janes,&nbsp;Samantha L Quaife","doi":"10.1177/23814683231163190","DOIUrl":"https://doi.org/10.1177/23814683231163190","url":null,"abstract":"<p><p><b>Background.</b> Personal autonomy in lung cancer screening is advocated internationally, but health systems diverge in their approach, mandating either shared decision making (with a health care professional) or individual decision making. Studies of other cancer screening programs have found that individual preferences for the level of involvement in screening decisions vary across different sociodemographic groups and that aligning approaches with individual preferences has the potential to improve uptake. <b>Method.</b> For the first time, we examined preferences for decision control among a cohort of UK-based high-risk lung cancer screening candidates (<i>N</i> = 727). We used descriptive statistics to report the distribution of preferences and chi-square tests to examine associations between decision preferences and sociodemographic variables. <b>Results.</b> Most (69.7%) preferred to be involved in the decision with varying degrees of input from a health care professional. Few (10.2%) wanted to make the decision alone. Preferences were also associated with educational attainment. <b>Conclusion.</b> These findings suggest one-size-fits-all approaches may be inadequate in meeting diverse preferences, particularly those placing sole onus on the individual.</p><p><strong>Highlights: </strong>Preferences for involvement in decision making about lung cancer screening are heterogeneous among high-risk individuals in the United Kingdom and vary by educational attainment.Further work is needed to understand how policy makers might implement hybrid approaches to accommodate individual preferences and optimize lung cancer screening program outcomes.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231163190"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9597017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"To Be or Not to Be"-Cardiopulmonary Resuscitation for Hospitalized People Who Have a Low Probability of Benefit: Qualitative Analysis of Semi-structured Interviews. “生存还是毁灭”——低获益概率住院患者的心肺复苏:半结构化访谈的定性分析。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231168589
Daniel Kobewka, Yasmin Lalani, Victoria Shaffer, Tolulope Adewole, Kiefer Lypka, Pete Wegier

Purpose: Our aim was to understand the decision making of patients in hospital who wanted cardiopulmonary resuscitation despite low probability of benefit.

Methods: We included patients admitted to general medical wards who had a low chance of surviving in-hospital cardiopulmonary resuscitation (CPR) and had an order in the chart to administer CPR. We developed an interview guide to explore participants' decision-making process, sources of information, and emotions associated with this decision.

Results: We developed 3 themes from the data. 1) "Life is worth living . . . for now": Participants describe their enjoyment of life and desire to carry on in their current state. 2) "Making sense of CPR outcomes": Participants saw CPR outcomes as binary, either they live, or they die; deciding not to receive CPR means choosing death. Participants were optimistic they would survive CPR and cited personal experience and TV as information sources. 3) "Decision process": Participants did not engage in shared decision making. Instead, they were asked a binary yes/no question with no reflection on their values or discussion about harms or benefits.

Limitations: The probability of successful CPR in our sample is unknown. Findings may be different in a population who is imminently dying but still requesting CPR.

Conclusions: Participants chose CPR because they perceived life as worth living and CPR as a chance worth taking. Participants did not want to be left in a severely debilitated state but did not have accurate information about this risk.

Implications: Decision making about CPR in-hospital can be improved if it is grounded in accurate risk understanding and the patient's values and wishes.

目的:我们的目的是了解住院患者在低获益概率情况下需要心肺复苏的决策。方法:我们纳入了住院普通病房的患者,他们在医院心肺复苏(CPR)中存活的机会很低,并且在病历中有进行心肺复苏的命令。我们开发了一份访谈指南,以探索参与者的决策过程、信息来源以及与此决策相关的情绪。结果:我们从数据中发展出3个主题。1)“生命值得活下去……“暂时”:参与者描述了他们对生活的享受,并希望在目前的状态下继续下去。2) “理解心肺复苏术的结果”:参与者认为心肺复苏术的结果是二元的,要么活着,要么死亡;决定不接受心肺复苏术就意味着选择死亡。参与者们乐观地认为自己能在心肺复苏术中存活下来,并将个人经历和电视作为信息来源。3)“决策过程”:参与者没有参与共同决策。相反,他们被问了一个二元的是或否问题,没有反思他们的价值观或讨论危害或利益。局限性:我们的样本中CPR成功的概率是未知的。对于即将死亡但仍要求心肺复苏术的人群,结果可能会有所不同。结论:参与者选择心肺复苏术是因为他们认为生命值得活下去,心肺复苏术是一个值得冒险的机会。参与者不希望被留在一个严重衰弱的状态,但没有关于这种风险的准确信息。结论:基于准确的风险理解和患者的价值观和愿望,可以改善院内心肺复苏术的决策。
{"title":"\"To Be or Not to Be\"-Cardiopulmonary Resuscitation for Hospitalized People Who Have a Low Probability of Benefit: Qualitative Analysis of Semi-structured Interviews.","authors":"Daniel Kobewka,&nbsp;Yasmin Lalani,&nbsp;Victoria Shaffer,&nbsp;Tolulope Adewole,&nbsp;Kiefer Lypka,&nbsp;Pete Wegier","doi":"10.1177/23814683231168589","DOIUrl":"https://doi.org/10.1177/23814683231168589","url":null,"abstract":"<p><strong>Purpose: </strong>Our aim was to understand the decision making of patients in hospital who wanted cardiopulmonary resuscitation despite low probability of benefit.</p><p><strong>Methods: </strong>We included patients admitted to general medical wards who had a low chance of surviving in-hospital cardiopulmonary resuscitation (CPR) and had an order in the chart to administer CPR. We developed an interview guide to explore participants' decision-making process, sources of information, and emotions associated with this decision.</p><p><strong>Results: </strong>We developed 3 themes from the data. 1) \"Life is worth living . . . for now\": Participants describe their enjoyment of life and desire to carry on in their current state. 2) \"Making sense of CPR outcomes\": Participants saw CPR outcomes as binary, either they live, or they die; deciding not to receive CPR means choosing death. Participants were optimistic they would survive CPR and cited personal experience and TV as information sources. 3) \"Decision process\": Participants did not engage in shared decision making. Instead, they were asked a binary yes/no question with no reflection on their values or discussion about harms or benefits.</p><p><strong>Limitations: </strong>The probability of successful CPR in our sample is unknown. Findings may be different in a population who is imminently dying but still requesting CPR.</p><p><strong>Conclusions: </strong>Participants chose CPR because they perceived life as worth living and CPR as a chance worth taking. Participants did not want to be left in a severely debilitated state but did not have accurate information about this risk.</p><p><strong>Implications: </strong>Decision making about CPR in-hospital can be improved if it is grounded in accurate risk understanding and the patient's values and wishes.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231168589"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/b7/10.1177_23814683231168589.PMC10141296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclusive Recruitment Strategies to Maximize Sociodemographic Diversity among Participants: A St. Louis Case Study. 最大限度地提高参与者社会人口多样性的包容性招聘策略:圣路易斯案例研究。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231183646
Chelsey R Carter, Julia Maki, Nicole Ackermann, Erika A Waters

Background. Sociodemographically diverse study samples are critical for research related to health decision making. However, not all researchers have the training, capacity, and funding to engage research methods that recruit the most diverse populations. Objective and Methods. We used participant-generated data, staff salary data, and participant observation to examine the effectiveness and cost of strategies that we used for screening, enrolling, and retaining a sociodemographically diverse sample for a risk communication and behavior change randomized controlled trial. Results. It took approximately 646 hours to contact 1,626 individuals and enroll 554 participants (505 of whom completed the baseline survey; 45.2% were members of a underrepresented racial/ethnic group, 19.4% had no college education, 49.5% were age 30-49 y). Retention at 90-d follow-up was 93%. The total cost was USD$19,898.50. The average cost was $35.92 per participant enrolled. In-person recruitment was most successful in identifying the largest proportion of screened and eligible participants who were members of underrepresented racial/ethnic populations (32.8% and 27.8%, respectively) and with no college experience (39.7% and 33.5%, respectively); it also had the highest total cost ($8,079.17). Existing research pools identified the largest proportion of younger participants (ages 30-49 y; 39.3% and 43.4% for screened and eligible, respectively). Existing listservs yielded the smallest proportion of individuals with no college experience and the fewest members of underrepresented racial/ethnic populations but had the lowest total cost ($290.33). Newspaper ads identified the fewest younger individuals and also had the highest cost per participant enrolled ($166.21). Word of mouth had the lowest cost per participant enrolled ($10.47). Conclusion. Results help medical decision-making researchers formulate recruitment plans that increase sociodemographic diversity in study samples. We also ask funders to accommodate increased costs required to maximize sociodemographic diversity in medical decision-making research.

Highlights: We provide concrete strategies for recruiting, enrolling, and retaining a sociodemographically diverse study sample.We offer cost estimates for all stages of study recruitment and found that in-person recruitment was the most effective, but also the most expensive, way to identify Black participants and participants with no college experience.It is critical for investigators to have access to institutional infrastructure and resources to support conducting research that is inclusive of diverse sociodemographic groups.An intentionally diverse recruitment staff supports a diverse study sample.

背景。社会人口统计学上多样化的研究样本对于与健康决策有关的研究至关重要。然而,并不是所有的研究人员都有培训、能力和资金来采用能够招募最多样化人群的研究方法。目的与方法。我们使用参与者生成的数据、员工工资数据和参与者观察来检查我们用于筛选、招募和保留社会人口统计学多样化样本的策略的有效性和成本,以进行风险沟通和行为改变随机对照试验。结果。研究人员花了大约646个小时联系了1626个人,并招募了554名参与者(其中505人完成了基线调查;45.2%是未被充分代表的种族/族裔群体的成员,19.4%没有受过大学教育,49.5%的人年龄在30-49岁之间。随访90 d时保留率为93%。总费用为19,898.50美元。每位参与者的平均费用为35.92美元。亲自招聘最成功地确定了被筛选和符合条件的参与者的最大比例,这些参与者是代表性不足的种族/民族人口(分别为32.8%和27.8%)和没有大学经历(分别为39.7%和33.5%);它的总成本也是最高的(8079.17美元)。现有的研究池确定了年轻参与者的比例最大(年龄在30-49岁;筛选者和合格者分别为39.3%和43.4%)。现有的榜单中,没有大学经历的个人所占比例最小,未被充分代表的种族/族裔人口所占比例最少,但总成本最低(290.33美元)。报纸广告发现的年轻人最少,每个参与者的报名成本也最高(166.21美元)。口碑营销的参与者人均注册成本最低(10.47美元)。结论。结果有助于医疗决策研究人员制定招聘计划,增加研究样本的社会人口多样性。我们还要求资助者适应医疗决策研究中最大化社会人口多样性所需的增加成本。重点:我们为招募、登记和保留社会人口统计学多样化的研究样本提供了具体的策略。我们为研究招募的所有阶段提供了成本估算,发现面对面的招募是最有效的,但也是最昂贵的,确定黑人参与者和没有大学经历的参与者的方式。至关重要的是,调查人员有机会获得机构基础设施和资源,以支持开展包括不同社会人口群体的研究。有意多样化的招聘人员支持多样化的研究样本。
{"title":"Inclusive Recruitment Strategies to Maximize Sociodemographic Diversity among Participants: A St. Louis Case Study.","authors":"Chelsey R Carter,&nbsp;Julia Maki,&nbsp;Nicole Ackermann,&nbsp;Erika A Waters","doi":"10.1177/23814683231183646","DOIUrl":"https://doi.org/10.1177/23814683231183646","url":null,"abstract":"<p><p><b>Background.</b> Sociodemographically diverse study samples are critical for research related to health decision making. However, not all researchers have the training, capacity, and funding to engage research methods that recruit the most diverse populations. <b>Objective and Methods.</b> We used participant-generated data, staff salary data, and participant observation to examine the effectiveness and cost of strategies that we used for screening, enrolling, and retaining a sociodemographically diverse sample for a risk communication and behavior change randomized controlled trial. <b>Results.</b> It took approximately 646 hours to contact 1,626 individuals and enroll 554 participants (505 of whom completed the baseline survey; 45.2% were members of a underrepresented racial/ethnic group, 19.4% had no college education, 49.5% were age 30-49 y). Retention at 90-d follow-up was 93%. The total cost was USD$19,898.50. The average cost was $35.92 per participant enrolled. In-person recruitment was most successful in identifying the largest proportion of screened and eligible participants who were members of underrepresented racial/ethnic populations (32.8% and 27.8%, respectively) and with no college experience (39.7% and 33.5%, respectively); it also had the highest total cost ($8,079.17). Existing research pools identified the largest proportion of younger participants (ages 30-49 y; 39.3% and 43.4% for screened and eligible, respectively). Existing listservs yielded the smallest proportion of individuals with no college experience and the fewest members of underrepresented racial/ethnic populations but had the lowest total cost ($290.33). Newspaper ads identified the fewest younger individuals and also had the highest cost per participant enrolled ($166.21). Word of mouth had the lowest cost per participant enrolled ($10.47). <b>Conclusion.</b> Results help medical decision-making researchers formulate recruitment plans that increase sociodemographic diversity in study samples. We also ask funders to accommodate increased costs required to maximize sociodemographic diversity in medical decision-making research.</p><p><strong>Highlights: </strong>We provide concrete strategies for recruiting, enrolling, and retaining a sociodemographically diverse study sample.We offer cost estimates for all stages of study recruitment and found that in-person recruitment was the most effective, but also the most expensive, way to identify Black participants and participants with no college experience.It is critical for investigators to have access to institutional infrastructure and resources to support conducting research that is inclusive of diverse sociodemographic groups.An intentionally diverse recruitment staff supports a diverse study sample.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231183646"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/a9/10.1177_23814683231183646.PMC10334001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10299548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures. 开发一个模型框架,用于量化外科手术中抗生素耐药性对健康和成本的影响。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231152885
Heather Davies, Joel Russell, Angel Varghese, Hayden Holmes, Marta O Soares, B Woods, Ruth Puig-Peiro, Stephanie Evans, Rory Tierney, Stuart Mealing, Mark Sculpher, Julie V Robotham

Background. Antimicrobial resistance (AMR) is a global public health threat. The wider implications of AMR, such as the impact of antibiotic resistance (ABR) on surgical procedures, are yet to be quantified. The objective of this study was to produce a conceptual modeling framework to provide a basis for estimating the current and potential future consequences of ABR for surgical procedures in England. Design. A framework was developed using literature-based evidence and structured expert elicitation. This was applied to populations undergoing emergency repair of the neck of the femur and elective colorectal resection surgery. Results. The framework captures the implications of increasing ABR by allowing for higher rates of surgical site infection (SSI) as the effectiveness of antibiotic prophylaxis wanes and worsened outcomes following SSIs to reflect reduced antibiotic treatment effectiveness. The expert elicitation highlights the uncertainty in quantifying the impact of ABR, reflected in the results. A hypothetical SSI rate increase of 14% in a person undergoing emergency repair of the femur could increase costs by 39% (-2% to 108% credible interval [CI]) and decrease quality-adjusted life-years by 11% (0.4% to 62% CI) over 15 y. Conclusions. The modeling framework is a starting point for addressing the implication of ABR on the outcomes and costs of surgeries. Due to clinical uncertainty highlighted in the expert elicitation process, the numerical outputs of the case studies should not be focused on but rather the framework itself, illustration of the evidence gaps, the benefit of expert elicitation in quantifying parameters with limited data, and the potential magnitude of the impact of ABR on surgical procedures. Implications. The framework can be used to support research surrounding the health and cost burden of ABR in England.

Highlights: The modeling framework is a starting point for assessing the health and cost impacts of antibiotic resistance on surgeries in England.Formulating a framework and synthesizing evidence to parameterize data gaps provides targets for future research.Once data gaps are addressed, this modeling framework can be used to feed into overall estimates of the health and cost burden of antibiotic resistance and evaluate control policies.

背景。抗菌素耐药性(AMR)是一个全球性的公共卫生威胁。抗生素耐药性的更广泛的影响,如抗生素耐药性(ABR)对外科手术的影响,还有待量化。本研究的目的是建立一个概念模型框架,为估计英国外科手术中ABR的当前和潜在未来后果提供基础。设计。使用基于文献的证据和结构化的专家启发开发了一个框架。这适用于接受股骨颈紧急修复和择期结肠直肠切除手术的人群。结果。随着抗生素预防效果的减弱,手术部位感染(SSI)发生率升高,该框架考虑到了ABR增加的影响,SSI后的预后恶化反映了抗生素治疗效果的降低。专家的启发强调了量化ABR影响的不确定性,反映在结果中。假设紧急股骨修复术患者SSI率增加14%,15年内成本增加39%(可信区间[CI] -2%至108%),质量调整生命年减少11% (CI 0.4%至62%)。建模框架是解决ABR对手术结果和成本影响的起点。由于专家引出过程中突出的临床不确定性,不应关注案例研究的数值输出,而应关注框架本身,证据差距的说明,专家引出在有限数据下量化参数的好处,以及ABR对外科手术的潜在影响程度。的影响。该框架可用于支持围绕英国ABR的健康和成本负担的研究。重点:建模框架是评估英格兰手术中抗生素耐药性对健康和成本影响的起点。制定一个框架和综合证据来参数化数据差距为未来的研究提供了目标。一旦数据缺口得到解决,该建模框架可用于对抗生素耐药性的健康和成本负担进行总体估计,并评估控制政策。
{"title":"Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures.","authors":"Heather Davies,&nbsp;Joel Russell,&nbsp;Angel Varghese,&nbsp;Hayden Holmes,&nbsp;Marta O Soares,&nbsp;B Woods,&nbsp;Ruth Puig-Peiro,&nbsp;Stephanie Evans,&nbsp;Rory Tierney,&nbsp;Stuart Mealing,&nbsp;Mark Sculpher,&nbsp;Julie V Robotham","doi":"10.1177/23814683231152885","DOIUrl":"https://doi.org/10.1177/23814683231152885","url":null,"abstract":"<p><p><b>Background.</b> Antimicrobial resistance (AMR) is a global public health threat. The wider implications of AMR, such as the impact of antibiotic resistance (ABR) on surgical procedures, are yet to be quantified. The objective of this study was to produce a conceptual modeling framework to provide a basis for estimating the current and potential future consequences of ABR for surgical procedures in England. <b>Design.</b> A framework was developed using literature-based evidence and structured expert elicitation. This was applied to populations undergoing emergency repair of the neck of the femur and elective colorectal resection surgery. <b>Results.</b> The framework captures the implications of increasing ABR by allowing for higher rates of surgical site infection (SSI) as the effectiveness of antibiotic prophylaxis wanes and worsened outcomes following SSIs to reflect reduced antibiotic treatment effectiveness. The expert elicitation highlights the uncertainty in quantifying the impact of ABR, reflected in the results. A hypothetical SSI rate increase of 14% in a person undergoing emergency repair of the femur could increase costs by 39% (-2% to 108% credible interval [CI]) and decrease quality-adjusted life-years by 11% (0.4% to 62% CI) over 15 y. <b>Conclusions.</b> The modeling framework is a starting point for addressing the implication of ABR on the outcomes and costs of surgeries. Due to clinical uncertainty highlighted in the expert elicitation process, the numerical outputs of the case studies should not be focused on but rather the framework itself, illustration of the evidence gaps, the benefit of expert elicitation in quantifying parameters with limited data, and the potential magnitude of the impact of ABR on surgical procedures. <b>Implications.</b> The framework can be used to support research surrounding the health and cost burden of ABR in England.</p><p><strong>Highlights: </strong>The modeling framework is a starting point for assessing the health and cost impacts of antibiotic resistance on surgeries in England.Formulating a framework and synthesizing evidence to parameterize data gaps provides targets for future research.Once data gaps are addressed, this modeling framework can be used to feed into overall estimates of the health and cost burden of antibiotic resistance and evaluate control policies.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231152885"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/d5/10.1177_23814683231152885.PMC9900655.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9252344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions. 使用关于多重风险的患者偏好数据为监管决策提供信息。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683221148715
J Felipe Montano-Campos, Juan Marcos Gonzalez, Timothy Rickert, Angelyn O Fairchild, Bennett Levitan, Shelby D Reed

Background and Objectives. Risk-tolerance measures from patient-preference studies typically focus on individual adverse events. We recently introduced an approach that extends maximum acceptable risk (MAR) calculations to simultaneous maximum acceptable risk thresholds (SMART) for multiple treatment-related risks. We extend these methods to include the computation and display of confidence intervals and apply the approach to 3 published discrete-choice experiments to evaluate its utility to inform regulatory decisions. Methods. We generate MAR estimates and SMART curves and compare them with trial-based benefit-risk profiles of select treatments for depression, psoriasis, and thyroid cancer. Results. In the depression study, SMART curves with 70% to 95% confidence intervals portray which combinations of 2 adverse events would be considered acceptable. In the psoriasis example, the asymmetric confidence intervals for the SMART curve indicate that relying on independent MARs versus SMART curves when there are nonlinear preferences can lead to decisions that could expose patients to greater risks than they would accept. The thyroid cancer application shows an example in which the clinical incidence of each of 3 adverse events is lower than the single-event MARs for the expected treatment benefit, yet the collective risk profile surpasses acceptable levels when considered jointly. Limitations. Nonrandom sample of studies. Conclusions. When evaluating conventional MARs in which the observed incidences are near the estimated MARs or where preferences demonstrate diminishing marginal disutility of risk, conventional MAR estimates will overstate risk acceptance, which could lead to misinformed decisions, potentially placing patients at greater risk of adverse events than they would accept. Implications. The SMART method, herein extended to include confidence intervals, provides a reproducible, transparent evidence-based approach to enable decision makers to use data from discrete-choice experiments to account for multiple adverse events.

Highlights: Estimates of maximum acceptable risk (MAR) for a defined treatment benefit can be useful to inform regulatory decisions; however, the conventional metric considers one adverse event at a time.This article applies a new approach known as SMART (simultaneous maximum acceptable risk thresholds) that accounts for multiple adverse events to 3 published discrete-choice experiments.Findings reveal that conventional MARs could lead decision makers to accept a treatment based on individual risks that would not be acceptable if multiple risks are considered simultaneously.

背景和目标。来自患者偏好研究的风险承受能力措施通常侧重于个体不良事件。我们最近引入了一种方法,将最大可接受风险(MAR)计算扩展到同时最大可接受风险阈值(SMART),用于多种治疗相关风险。我们将这些方法扩展到包括置信区间的计算和显示,并将该方法应用于3个已发表的离散选择实验,以评估其为监管决策提供信息的效用。方法。我们生成MAR估计值和SMART曲线,并将其与抑郁症、牛皮癣和甲状腺癌选定治疗方法的基于试验的获益-风险概况进行比较。结果。在抑郁症研究中,SMART曲线以70%到95%的置信区间描绘了两种不良事件的哪一种组合被认为是可接受的。在牛皮癣的例子中,SMART曲线的不对称置信区间表明,当存在非线性偏好时,依赖独立的MARs曲线与SMART曲线可能导致患者面临比他们接受的更大风险的决策。甲状腺癌的应用显示了一个例子,其中3种不良事件中的每一种的临床发生率都低于预期治疗获益的单事件MARs,但当联合考虑时,集体风险概况超过了可接受的水平。的局限性。研究的非随机样本。结论。当评估常规的MARs时,观察到的发生率接近估计的MARs,或者偏好显示风险的边际负效用递减,传统的MARs估计会夸大风险接受度,这可能导致错误的决策,潜在地使患者面临比他们接受的更大的不良事件风险。的影响。SMART方法,在此扩展到包括置信区间,提供了一种可重复的、透明的基于证据的方法,使决策者能够使用离散选择实验的数据来解释多种不良事件。重点:对确定治疗获益的最大可接受风险(MAR)的估计可用于告知监管决策;然而,传统的度量标准一次只考虑一个不良事件。本文采用了一种被称为SMART(同时最大可接受风险阈值)的新方法,该方法对3个已发表的离散选择实验中的多个不良事件进行了解释。研究结果表明,传统的MARs可能导致决策者接受基于个体风险的治疗,而如果同时考虑多种风险,这种治疗是不可接受的。
{"title":"Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions.","authors":"J Felipe Montano-Campos,&nbsp;Juan Marcos Gonzalez,&nbsp;Timothy Rickert,&nbsp;Angelyn O Fairchild,&nbsp;Bennett Levitan,&nbsp;Shelby D Reed","doi":"10.1177/23814683221148715","DOIUrl":"https://doi.org/10.1177/23814683221148715","url":null,"abstract":"<p><p><b>Background and Objectives.</b> Risk-tolerance measures from patient-preference studies typically focus on individual adverse events. We recently introduced an approach that extends maximum acceptable risk (MAR) calculations to simultaneous maximum acceptable risk thresholds (SMART) for multiple treatment-related risks. We extend these methods to include the computation and display of confidence intervals and apply the approach to 3 published discrete-choice experiments to evaluate its utility to inform regulatory decisions. <b>Methods.</b> We generate MAR estimates and SMART curves and compare them with trial-based benefit-risk profiles of select treatments for depression, psoriasis, and thyroid cancer. <b>Results.</b> In the depression study, SMART curves with 70% to 95% confidence intervals portray which combinations of 2 adverse events would be considered acceptable. In the psoriasis example, the asymmetric confidence intervals for the SMART curve indicate that relying on independent MARs versus SMART curves when there are nonlinear preferences can lead to decisions that could expose patients to greater risks than they would accept. The thyroid cancer application shows an example in which the clinical incidence of each of 3 adverse events is lower than the single-event MARs for the expected treatment benefit, yet the collective risk profile surpasses acceptable levels when considered jointly. <b>Limitations.</b> Nonrandom sample of studies. <b>Conclusions.</b> When evaluating conventional MARs in which the observed incidences are near the estimated MARs or where preferences demonstrate diminishing marginal disutility of risk, conventional MAR estimates will overstate risk acceptance, which could lead to misinformed decisions, potentially placing patients at greater risk of adverse events than they would accept. <b>Implications.</b> The SMART method, herein extended to include confidence intervals, provides a reproducible, transparent evidence-based approach to enable decision makers to use data from discrete-choice experiments to account for multiple adverse events.</p><p><strong>Highlights: </strong>Estimates of maximum acceptable risk (MAR) for a defined treatment benefit can be useful to inform regulatory decisions; however, the conventional metric considers one adverse event at a time.This article applies a new approach known as SMART (simultaneous maximum acceptable risk thresholds) that accounts for multiple adverse events to 3 published discrete-choice experiments.Findings reveal that conventional MARs could lead decision makers to accept a treatment based on individual risks that would not be acceptable if multiple risks are considered simultaneously.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683221148715"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/fe/10.1177_23814683221148715.PMC9841858.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10604155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Beyond High-Income Countries: Low Numeracy Is Associated with Older Adult Age around the World. 在高收入国家之外:世界各地的低计算能力与老年人有关。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231174241
Wändi Bruine de Bruin, Aulona Ulqinaku, Jimena Llopis, Matteo Santangelo Ravà

Background: Numeracy, or the ability to understand and use numbers, has been associated with obtaining better health and financial outcomes. Studies in high-income countries suggest that low numeracy is associated with older age-perhaps especially among individuals with lower education. Here, we examined whether findings generalize to the rest of the world.

Methods: Gallup surveyed >150,000 participants for the 2019 Lloyd's Register Foundation World Risk Poll, from 21 low-income, 34 lower-middle income, 42 upper-middle income, and 43 high-income countries. Low numeracy was operationalized as failing to correctly answer, "Is 10% bigger than 1 out of 10, smaller than 1 out of 10, or the same as 1 out of 10?"

Results: Regressions controlling for participants' education, income, and other characteristics found that, worldwide, low numeracy was associated with older age, lower education, and their interaction. Findings held in each country-income category, although low numeracy was more common in low-income countries than in high-income countries.

Limitations: Age differences may reflect cohort effects and life span-developmental changes.

Discussion: Low numeracy is more common among people who are older and less educated. We discuss the need for education and interventions outside of the classroom.

Highlights: We analyzed a global survey conducted in 21 low-income, 34 lower-middle income, 42 upper-middle income, and 43 high-income countries.Low numeracy was associated with older adult age, even after accounting for age differences in education.Low numeracy was more common in older people with lower education.

背景:计算能力,或理解和使用数字的能力,与获得更好的健康和财务结果有关。高收入国家的研究表明,较低的计算能力与年龄的增长有关——尤其是在受教育程度较低的人群中。在这里,我们研究了这些发现是否可以推广到世界其他地区。方法:盖洛普对来自21个低收入国家、34个中低收入国家、42个中高收入国家和43个高收入国家的15万名参与者进行了2019年劳氏基金会世界风险调查。低计算能力被操作化为不能正确回答“10%是大于1 / 10,小于1 / 10,还是等于1 / 10?”结果:控制参与者的教育、收入和其他特征的回归发现,在世界范围内,低计算能力与年龄较大、受教育程度较低及其相互作用有关。尽管低计算能力在低收入国家比在高收入国家更为普遍,但每个国家的收入类别都有不同的发现。局限性:年龄差异可能反映队列效应和寿命发育变化。讨论:计算能力低下在年龄较大和受教育程度较低的人群中更为常见。我们讨论了课堂外教育和干预的必要性。重点:我们分析了在21个低收入国家、34个中低收入国家、42个中高收入国家和43个高收入国家进行的一项全球调查。即使考虑到受教育程度的年龄差异,计算能力低下与年龄较大有关。低计算能力在受教育程度较低的老年人中更为常见。
{"title":"Beyond High-Income Countries: Low Numeracy Is Associated with Older Adult Age around the World.","authors":"Wändi Bruine de Bruin,&nbsp;Aulona Ulqinaku,&nbsp;Jimena Llopis,&nbsp;Matteo Santangelo Ravà","doi":"10.1177/23814683231174241","DOIUrl":"https://doi.org/10.1177/23814683231174241","url":null,"abstract":"<p><strong>Background: </strong>Numeracy, or the ability to understand and use numbers, has been associated with obtaining better health and financial outcomes. Studies in high-income countries suggest that low numeracy is associated with older age-perhaps especially among individuals with lower education. Here, we examined whether findings generalize to the rest of the world.</p><p><strong>Methods: </strong>Gallup surveyed >150,000 participants for the 2019 Lloyd's Register Foundation World Risk Poll, from 21 low-income, 34 lower-middle income, 42 upper-middle income, and 43 high-income countries. Low numeracy was operationalized as failing to correctly answer, \"Is 10% bigger than 1 out of 10, smaller than 1 out of 10, or the same as 1 out of 10?\"</p><p><strong>Results: </strong>Regressions controlling for participants' education, income, and other characteristics found that, worldwide, low numeracy was associated with older age, lower education, and their interaction. Findings held in each country-income category, although low numeracy was more common in low-income countries than in high-income countries.</p><p><strong>Limitations: </strong>Age differences may reflect cohort effects and life span-developmental changes.</p><p><strong>Discussion: </strong>Low numeracy is more common among people who are older and less educated. We discuss the need for education and interventions outside of the classroom.</p><p><strong>Highlights: </strong>We analyzed a global survey conducted in 21 low-income, 34 lower-middle income, 42 upper-middle income, and 43 high-income countries.Low numeracy was associated with older adult age, even after accounting for age differences in education.Low numeracy was more common in older people with lower education.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231174241"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/6f/10.1177_23814683231174241.PMC10363889.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9875711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. 英夫利昔单抗定价在炎症性肠病的国际经济评估中为生物和生物仿制药准入政策提供信息:一项系统综述。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231156433
Naazish S Bashir, Avery Hughes, Wendy J Ungar
<p><p><b>Background.</b> Policies mandating the use of lower cost biosimilars in patients with inflammatory bowel disease (IBD) have created concerns for patients who prefer their original biologic. <b>Purpose.</b> To inform the cost-effectiveness of biosimilar infliximab treatment in IBD by systematically reviewing the effect of infliximab price variation on cost-effectiveness for jurisdictional decision making. <b>Data Sources.</b> MEDLINE, Embase, Healthstar, Allied and Complementary Medicine, Joanna Briggs Institute EBP Database, International Pharmaceutical Abstracts, Health and Psychosocial Instruments, Mental Measurements Yearbook citation databases, PEDE, CEA registry, HTA agencies. <b>Study Selection.</b> Economic evaluations of infliximab for adult or pediatric Crohn's disease and/or ulcerative colitis published from 1998 through 2019 in which drug price was varied in sensitivity analysis were included. <b>Data Extraction.</b> Study characteristics, main findings, and results of drug price sensitivity analyses were extracted. Studies were critically appraised. The cost-effective price of infliximab was determined based on the stated willingness-to-pay (WTP) thresholds for each jurisdiction. <b>Data Synthesis.</b> Infliximab price was examined in sensitivity analysis in 31 studies. Infliximab showed favorable cost-effectiveness at a price ranging from CAD $66 to $1,260 per vial, depending on jurisdiction. A total of 18 studies (58%) demonstrated cost-effectiveness ratios above the jurisdictional WTP threshold. <b>Limitations.</b> Drug prices were not always reported separately, WTP thresholds varied, and funding sources were not consistently reported. <b>Conclusion.</b> Despite the high cost of infliximab, few economic evaluations examined price variation, limiting the ability to infer the effects of biosimilar introduction. Alternative pricing strategies and access to treatment could be considered to enable IBD patients to maintain access to their current medications.</p><p><strong>Highlights: </strong>In an effort to reduce public drug expenditures, Canadian and other jurisdictional drug plans have mandated the use of lower cost, but similarly effective, biosimilars in patients with newly diagnosed inflammatory bowel disease or require a nonmedical switch for established patients. This switch has created concerns for patients and clinicians who want to maintain the ability to make treatment decisions and remain with the original biologic.It is customary for economic evaluations to assess the robustness of results to variations in high-cost items such as medications. In the absence of economic evaluations of biosimilars, examining biologic drug price in sensitivity analysis provides insight into the cost-effectiveness of biosimilar alternatives. A total of 31 economic evaluations of infliximab for the treatment of inflammatory bowel disease varied the infliximab price in sensitivity analysis.The infliximab price deemed to be cost-effect
背景。要求在炎症性肠病(IBD)患者中使用成本较低的生物类似药的政策引起了更喜欢原生物仿制药的患者的关注。目的。通过系统回顾英夫利昔单抗价格变化对司法决策成本效益的影响,了解生物仿制药英夫利昔单抗治疗IBD的成本效益。数据源。MEDLINE, Embase, Healthstar, Allied and Complementary Medicine, Joanna Briggs Institute EBP数据库,国际药物摘要,健康与社会心理仪器,心理测量年鉴引文数据库,PEDE, CEA注册,HTA机构。研究选择。纳入1998年至2019年发表的英夫利昔单抗治疗成人或儿童克罗恩病和/或溃疡性结肠炎的经济评估,其中药物价格在敏感性分析中有所不同。数据提取。提取研究特点、主要发现及药品价格敏感性分析结果。对研究进行了批判性评价。英夫利昔单抗的成本效益价格是根据每个管辖区规定的支付意愿(WTP)阈值确定的。合成数据。31项研究对英夫利昔单抗的价格进行了敏感性分析。英夫利昔单抗显示出良好的成本效益,价格从每瓶66加元到1260加元不等,取决于司法管辖区。共有18项研究(58%)表明成本效益比高于辖区WTP阈值。的局限性。药品价格并非总是单独报告,WTP阈值各不相同,资金来源也没有一致报告。结论。尽管英夫利昔单抗的成本很高,但很少有经济评估检查价格变化,限制了推断生物仿制药引入效果的能力。可以考虑采用替代定价策略和获得治疗,使IBD患者能够继续获得他们目前的药物。亮点:为了减少公共药物支出,加拿大和其他司法管辖区的药物计划已强制要求在新诊断的炎症性肠病患者中使用成本较低但同样有效的生物仿制药,或要求对已确诊的患者进行非医疗转换。这种转变引起了患者和临床医生的关注,他们希望保持做出治疗决定的能力,并继续使用原始的生物制剂。经济评估通常是评估结果对高成本项目(如药物)变化的稳健性。在缺乏生物仿制药的经济评估的情况下,在敏感性分析中检查生物药物价格可以深入了解生物仿制药替代品的成本效益。共有31项对英夫利昔单抗治疗炎症性肠病的经济评价在敏感性分析中改变了英夫利昔单抗的价格。在每项研究中,英夫利昔单抗被认为具有成本效益的价格从每100毫克瓶66加元到1,260加元不等。共有18项研究(58%)表明,增量成本效益比高于辖区支付意愿阈值。如果政策决定是基于价格,那么原始制造商可以考虑降低价格或协商替代定价模式,以使炎症性肠病患者能够继续使用他们目前的药物。
{"title":"Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review.","authors":"Naazish S Bashir,&nbsp;Avery Hughes,&nbsp;Wendy J Ungar","doi":"10.1177/23814683231156433","DOIUrl":"https://doi.org/10.1177/23814683231156433","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Background.&lt;/b&gt; Policies mandating the use of lower cost biosimilars in patients with inflammatory bowel disease (IBD) have created concerns for patients who prefer their original biologic. &lt;b&gt;Purpose.&lt;/b&gt; To inform the cost-effectiveness of biosimilar infliximab treatment in IBD by systematically reviewing the effect of infliximab price variation on cost-effectiveness for jurisdictional decision making. &lt;b&gt;Data Sources.&lt;/b&gt; MEDLINE, Embase, Healthstar, Allied and Complementary Medicine, Joanna Briggs Institute EBP Database, International Pharmaceutical Abstracts, Health and Psychosocial Instruments, Mental Measurements Yearbook citation databases, PEDE, CEA registry, HTA agencies. &lt;b&gt;Study Selection.&lt;/b&gt; Economic evaluations of infliximab for adult or pediatric Crohn's disease and/or ulcerative colitis published from 1998 through 2019 in which drug price was varied in sensitivity analysis were included. &lt;b&gt;Data Extraction.&lt;/b&gt; Study characteristics, main findings, and results of drug price sensitivity analyses were extracted. Studies were critically appraised. The cost-effective price of infliximab was determined based on the stated willingness-to-pay (WTP) thresholds for each jurisdiction. &lt;b&gt;Data Synthesis.&lt;/b&gt; Infliximab price was examined in sensitivity analysis in 31 studies. Infliximab showed favorable cost-effectiveness at a price ranging from CAD $66 to $1,260 per vial, depending on jurisdiction. A total of 18 studies (58%) demonstrated cost-effectiveness ratios above the jurisdictional WTP threshold. &lt;b&gt;Limitations.&lt;/b&gt; Drug prices were not always reported separately, WTP thresholds varied, and funding sources were not consistently reported. &lt;b&gt;Conclusion.&lt;/b&gt; Despite the high cost of infliximab, few economic evaluations examined price variation, limiting the ability to infer the effects of biosimilar introduction. Alternative pricing strategies and access to treatment could be considered to enable IBD patients to maintain access to their current medications.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;In an effort to reduce public drug expenditures, Canadian and other jurisdictional drug plans have mandated the use of lower cost, but similarly effective, biosimilars in patients with newly diagnosed inflammatory bowel disease or require a nonmedical switch for established patients. This switch has created concerns for patients and clinicians who want to maintain the ability to make treatment decisions and remain with the original biologic.It is customary for economic evaluations to assess the robustness of results to variations in high-cost items such as medications. In the absence of economic evaluations of biosimilars, examining biologic drug price in sensitivity analysis provides insight into the cost-effectiveness of biosimilar alternatives. A total of 31 economic evaluations of infliximab for the treatment of inflammatory bowel disease varied the infliximab price in sensitivity analysis.The infliximab price deemed to be cost-effect","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231156433"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/a3/10.1177_23814683231156433.PMC9969457.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating and Supporting Patient and Caregiver Sensemaking in Complex Medical Decisions Using Participatory Design. 使用参与式设计调查和支持复杂医疗决策中的患者和护理人员感知。
Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/23814683231164988
Sarah Fadem

Background. Patients and caregivers facing complex health decisions must make sense of unfamiliar, emotionally challenging information and experiences. For patients with hematological malignancy, bone marrow transplant (BMT) may be the best chance for a cure but has significant risk of morbidity and mortality. This study aimed to investigate and support patient and caregiver sensemaking as they consider BMT. Methods. Ten BMT patients and 5 caregivers engaged in remote participatory design (PD) workshops. Participants drew timelines of their memorable experiences leading up to BMT. Then, they used transparency paper to annotate their timelines and design improvements to this process. Results. Thematic analysis of drawings and transcripts revealed a 3-phase sensemaking process. In phase 1, participants were introduced to BMT and understood it as a possibility, not an inevitability. In phase 2, they focused on meeting prerequisites including remission and donor identification. Participants came to believe they needed transplant, consequently describing BMT not as a decision between viable options, but that transplant was their "only chance" for survival. In phase 3, participants attended an orientation detailing the extensive risks of transplant, leading to anxiety and doubt. Participants designed solutions that provided reassurance to those grappling with the life-altering impacts of transplant. Conclusions. For patients and caregivers navigating complex health decisions, sensemaking is a dynamic, ongoing process that affects expectations and emotional well-being. Interventions targeting reassurance alongside risk information can alleviate emotional impact and facilitate expectation development. The integration of PD and sensemaking methodologies enables participants to create holistic, tangible representations of experiences while empowering stakeholder engagement in intervention design. This method could be applied to other complex medical contexts to understand lived experiences and develop effective support interventions.

Highlights: Bone marrow transplant patients and caregivers experienced an evolving, emotionally challenging process of gradually understanding the transplant procedure and its risks.The solutions that participants designed centered on providing reassurance alongside risk information, suggesting future interventions could target emotional support as patients attempt to meet prerequisites and grapple with the risks of the potentially curative procedure.By viewing the challenges of complex medical decisions in terms of sensemaking and applying visual methods such as participatory design, researchers can facilitate expression of the dynamic, multifaceted, emotional components of experience and empower stakeholder involvement in intervention design.

背景。面对复杂健康决策的患者和护理人员必须理解不熟悉的、情感上具有挑战性的信息和经历。对于恶性血液病患者,骨髓移植(BMT)可能是治愈的最佳机会,但有显著的发病率和死亡率风险。本研究旨在调查和支持患者和护理人员在考虑BMT时的意义生成。方法。10名BMT患者和5名护理人员参与了远程参与式设计(PD)研讨会。参与者绘制了他们在BMT之前的难忘经历的时间表。然后,他们用透明纸标注他们的时间表,并设计改进这一过程。结果。对图纸和抄本的专题分析揭示了一个三阶段的意义生成过程。在第一阶段,参与者被介绍给BMT,并将其理解为一种可能性,而不是不可避免的。在第二阶段,他们专注于满足先决条件,包括缓解和捐赠者识别。参与者开始相信他们需要移植,因此将BMT描述为不是在可行的选择之间的决定,而是移植是他们生存的“唯一机会”。在第三阶段,参与者参加了一个详细介绍移植风险的培训,导致焦虑和怀疑。参与者设计了解决方案,为那些正在努力应对移植改变生活影响的人提供了保证。结论。对于患者和护理人员来说,做出复杂的健康决定是一个动态的、持续的过程,它会影响期望和情感健康。以保证和风险信息为目标的干预措施可以减轻情绪影响,促进期望的发展。PD和语义生成方法的整合使参与者能够创建整体的、有形的经验表示,同时授权利益相关者参与干预设计。这种方法可以应用于其他复杂的医疗环境,以了解生活经验和制定有效的支持干预措施。重点:骨髓移植患者和护理人员经历了一个不断发展的,情感上具有挑战性的过程,逐渐了解移植程序及其风险。参与者设计的解决方案以提供安心和风险信息为中心,表明未来的干预措施可以针对情感支持,因为患者试图满足先决条件,并努力应对潜在治疗过程的风险。通过观察复杂医疗决策在意义构建方面的挑战,并应用参与式设计等视觉方法,研究人员可以促进动态的、多方面的、情感的体验成分的表达,并授权利益相关者参与干预设计。
{"title":"Investigating and Supporting Patient and Caregiver Sensemaking in Complex Medical Decisions Using Participatory Design.","authors":"Sarah Fadem","doi":"10.1177/23814683231164988","DOIUrl":"https://doi.org/10.1177/23814683231164988","url":null,"abstract":"<p><p><b>Background.</b> Patients and caregivers facing complex health decisions must make sense of unfamiliar, emotionally challenging information and experiences. For patients with hematological malignancy, bone marrow transplant (BMT) may be the best chance for a cure but has significant risk of morbidity and mortality. This study aimed to investigate and support patient and caregiver sensemaking as they consider BMT. <b>Methods.</b> Ten BMT patients and 5 caregivers engaged in remote participatory design (PD) workshops. Participants drew timelines of their memorable experiences leading up to BMT. Then, they used transparency paper to annotate their timelines and design improvements to this process. <b>Results.</b> Thematic analysis of drawings and transcripts revealed a 3-phase sensemaking process. In phase 1, participants were introduced to BMT and understood it as a possibility, not an inevitability. In phase 2, they focused on meeting prerequisites including remission and donor identification. Participants came to believe they needed transplant, consequently describing BMT not as a decision between viable options, but that transplant was their \"only chance\" for survival. In phase 3, participants attended an orientation detailing the extensive risks of transplant, leading to anxiety and doubt. Participants designed solutions that provided reassurance to those grappling with the life-altering impacts of transplant. <b>Conclusions.</b> For patients and caregivers navigating complex health decisions, sensemaking is a dynamic, ongoing process that affects expectations and emotional well-being. Interventions targeting reassurance alongside risk information can alleviate emotional impact and facilitate expectation development. The integration of PD and sensemaking methodologies enables participants to create holistic, tangible representations of experiences while empowering stakeholder engagement in intervention design. This method could be applied to other complex medical contexts to understand lived experiences and develop effective support interventions.</p><p><strong>Highlights: </strong>Bone marrow transplant patients and caregivers experienced an evolving, emotionally challenging process of gradually understanding the transplant procedure and its risks.The solutions that participants designed centered on providing reassurance alongside risk information, suggesting future interventions could target emotional support as patients attempt to meet prerequisites and grapple with the risks of the potentially curative procedure.By viewing the challenges of complex medical decisions in terms of sensemaking and applying visual methods such as participatory design, researchers can facilitate expression of the dynamic, multifaceted, emotional components of experience and empower stakeholder involvement in intervention design.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"8 1","pages":"23814683231164988"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/a5/10.1177_23814683231164988.PMC10107376.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9753403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
MDM Policy and Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1